Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Condition:   Latent Tuberculosis Infection Interventions:   Biological: Recombinant Mycobacterium Tuberculosis Fusion Protein;   Biological: Purified Protein Derivative of Tuberculin Sponsors:   Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.;   Shenzhen Third People's Hospital;   Wuhan Institute for Tuberculosis Control Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials